Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 573

1.

Suppression of Nuclear Factor-κB by Glucocorticoid Receptor Blocks Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.

Fan P, Siwak DR, Abderrahman B, Agboke FA, Yerrum S, Jordan VC.

Mol Cancer Ther. 2019 Oct;18(10):1684-1695. doi: 10.1158/1535-7163.MCT-18-1363. Epub 2019 Sep 11.

PMID:
31511352
2.

Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.

Erstad DJ, Ramsay IA, Jordan VC, Sojoodi M, Fuchs BC, Tanabe KK, Caravan P, Gale EM.

Invest Radiol. 2019 Nov;54(11):697-703. doi: 10.1097/RLI.0000000000000593.

PMID:
31356382
3.

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

Goetz MP, Suman VJ, Nakamura Y, Kiyotani K, Jordan VC, Ingle JN.

J Clin Oncol. 2019 Aug 1;37(22):1982-1983. doi: 10.1200/JCO.19.00504. Epub 2019 Jun 18. No abstract available.

PMID:
31211604
4.

ASO Author Reflections: An Optimal Biological Model for Successful Drug Discovery.

Jordan VC.

Ann Surg Oncol. 2019 Jul;26(7):1991-1992. doi: 10.1245/s10434-019-07337-4. Epub 2019 Apr 17. No abstract available.

PMID:
30997629
5.

The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture.

Jordan VC.

Ann Surg Oncol. 2019 Jul;26(7):1981-1990. doi: 10.1245/s10434-019-07291-1. Epub 2019 Mar 25.

PMID:
30911948
6.

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.

Yoo B, Jordan VC, Sheedy P, Billig AM, Ross A, Pantazopoulos P, Medarova Z.

Sci Rep. 2019 Mar 18;9(1):4712. doi: 10.1038/s41598-019-41251-9.

7.

Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex.

Wang H, Jordan VC, Ramsay IA, Sojoodi M, Fuchs BC, Tanabe KK, Caravan P, Gale EM.

J Am Chem Soc. 2019 Apr 10;141(14):5916-5925. doi: 10.1021/jacs.9b00603. Epub 2019 Mar 28.

8.

Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein.

Sengupta S, Sevigny CM, Bhattacharya P, Jordan VC, Clarke R.

Mol Cancer Res. 2019 Apr;17(4):918-928. doi: 10.1158/1541-7786.MCR-18-0481. Epub 2019 Jan 17.

PMID:
30655322
9.

Moving Precision Oncology Forward Amid Myths and Misconceptions.

Abderrahman B, Jordan VC.

JAMA Oncol. 2018 Dec 1;4(12):1789-1790. doi: 10.1001/jamaoncol.2018.5067. No abstract available.

PMID:
30419081
10.

Zinc as an Imaging Biomarker of Prostate Cancer.

Lo ST, Martins AF, Jordan VC, Sherry AD.

Isr J Chem. 2017 Sep;57(9):854-861. doi: 10.1002/ijch.201700043. Epub 2017 Jul 31.

11.

Lanthanide DO3A-tropone complexes: efficient dual MR/NIR imaging probes in aqueous medium.

Hashami Z, Martins AF, Funk AM, Jordan VC, Petoud S, Eliseeva SV, Kovacs Z.

Eur J Inorg Chem. 2017 Nov 23;2017(43):4965-4968. doi: 10.1002/ejic.201701003. Epub 2017 Aug 24.

12.

Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells.

Fan P, Abderrahman B, Chai TS, Yerrum S, Jordan VC.

Mol Cancer Ther. 2018 Dec;17(12):2732-2745. doi: 10.1158/1535-7163.MCT-18-0088. Epub 2018 Sep 17.

PMID:
30224430
13.

How PERK kinase conveys stress signals to nuclear factor-κB to mediate estrogen-induced apoptosis in breast cancer cells?

Fan P, Jordan VC.

Cell Death Dis. 2018 Aug 13;9(8):842. doi: 10.1038/s41419-018-0516-y. No abstract available.

14.

Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women's Health.

Abderrahman B, Jordan VC.

Endocrinology. 2018 Aug 1;159(8):2980-2990. doi: 10.1210/en.2018-00263. Review.

PMID:
29931061
15.

Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.

Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF, Rincon DMQ, Greenland JA, Rajan SS, Greene GL, Jordan VC.

Mol Pharmacol. 2018 Aug;94(2):812-822. doi: 10.1124/mol.117.111385. Epub 2018 May 8.

16.

Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive.

Jordan VC.

Clin Cancer Res. 2018 Aug 1;24(15):3480-3482. doi: 10.1158/1078-0432.CCR-18-0759. Epub 2018 Apr 19.

17.

Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells.

Fan P, Tyagi AK, Agboke FA, Mathur R, Pokharel N, Jordan VC.

Cell Death Discov. 2018 Feb 12;4:15. doi: 10.1038/s41420-017-0012-7. eCollection 2018 Dec.

18.

The Study of Letrozole Extension (SOLE) revisited.

Jordan VC.

Lancet Oncol. 2018 Feb;19(2):e77. doi: 10.1016/S1470-2045(18)30028-7. No abstract available.

PMID:
29413478
19.

Telling details of breast-cancer recurrence.

Abderrahman B, Jordan VC.

Nature. 2018 Jan 11;553(7687):155. doi: 10.1038/d41586-018-00399-6. No abstract available.

PMID:
29323320
20.

A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.

Maximov PY, Abderrahman B, Curpan RF, Hawsawi YM, Fan P, Jordan VC.

Endocr Relat Cancer. 2018 Feb;25(2):R83-R113. doi: 10.1530/ERC-17-0416. Epub 2017 Nov 21. Review.

21.

Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer.

Abderrahman B, Jordan VC.

JAMA Oncol. 2018 Jan 1;4(1):15-16. doi: 10.1001/jamaoncol.2017.3510. No abstract available.

PMID:
29145574
22.

Endoxifen: The End, or Are We at the Beginning?

Jordan VC.

J Clin Oncol. 2017 Oct 20;35(30):3378-3379. doi: 10.1200/JCO.2017.74.9325. Epub 2017 Aug 30. No abstract available.

PMID:
28854071
23.

Angela M. Hartley Brodie (1934-2017).

Abderrahman B, Jordan VC.

Nature. 2017 Aug 2;548(7665):32. doi: 10.1038/548032a. No abstract available.

PMID:
28770835
24.

Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer.

Jordan VC.

JAMA Oncol. 2017 Aug 1;3(8):1141. doi: 10.1001/jamaoncol.2017.2074. No abstract available.

PMID:
28727870
25.

Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?

Bhattacharya P, Abderrahman B, Jordan VC.

Expert Rev Anticancer Ther. 2017 Apr;17(4):297-310. doi: 10.1080/14737140.2017.1297233. Epub 2017 Mar 10.

PMID:
28281842
26.

The 4Ps of Breast Cancer Chemoprevention: Putting Proven Principles into Practice.

Jordan VC.

Cancer Prev Res (Phila). 2017 Apr;10(4):219-222. doi: 10.1158/1940-6207.CAPR-17-0026. Epub 2017 Feb 28.

27.

Tamoxifen Decreases Mortality, but How?

Bhattacharya P, Abderrahman B, Jordan VC.

J Clin Oncol. 2017 Jan 20;35(3):379. doi: 10.1200/JCO.2016.69.1618. Epub 2016 Oct 31. No abstract available.

PMID:
28095275
28.

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.

Obiorah I, Sengupta S, Fan P, Jordan VC.

Br J Cancer. 2016 Oct 25;115(9):e10. doi: 10.1038/bjc.2016.298. Epub 2016 Oct 6. No abstract available.

29.

Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.

Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC.

Br J Cancer. 2016 Oct 25;115(9):e12. doi: 10.1038/bjc.2016.297. Epub 2016 Sep 22. No abstract available.

30.

Long-term Adjuvant Tamoxifen Therapy and Decreases in Contralateral Breast Cancer.

Abderrahman B, Jordan VC.

JAMA Oncol. 2017 Feb 1;3(2):163-164. doi: 10.1001/jamaoncol.2016.3324. No abstract available.

PMID:
27711910
31.

Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer.

Hoppe R, Fan P, Büttner F, Winter S, Tyagi AK, Cunliffe H, Jordan VC, Brauch H.

Oncotarget. 2016 Nov 1;7(44):71235-71254. doi: 10.18632/oncotarget.12103.

32.

Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.

Jordan VC, Fan P, Abderrahman B, Maximov PY, Hawsawi YM, Bhattacharya P, Pokharel N.

Discov Med. 2016 May;21(117):411-27.

33.

A Raloxifene Withdrawal Response: Translational Research, Definitions, and Clinical Applications.

Jordan VC.

Integr Cancer Ther. 2016 Sep;15(3):242-4. doi: 10.1177/1534735416651329. Epub 2016 Jun 7. No abstract available.

34.

Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity.

Abderrahman B, Jordan VC.

J Clin Oncol. 2016 Aug 1;34(22):2675-6. doi: 10.1200/JCO.2016.67.3137. Epub 2016 May 23. No abstract available.

PMID:
27217463
35.

A Retrospective: On Clinical Studies with 5-Fluorouracil.

Jordan VC.

Cancer Res. 2016 Feb 15;76(4):767-8. doi: 10.1158/0008-5472.CAN-16-0150. No abstract available.

36.

Differing Perspectives on Breast Cancer Chemoprevention.

Jordan VC.

JAMA Oncol. 2016 Feb;2(2):276. doi: 10.1001/jamaoncol.2015.3906. No abstract available.

PMID:
26868999
37.

The modulation of estrogen-induced apoptosis as an interpretation of the women's health initiative trials.

Abderrahman B, Jordan VC.

Expert Rev Endocrinol Metab. 2016 Jan;11(1):81-86. doi: 10.1586/17446651.2016.1128324. Epub 2015 Dec 23.

38.

Progesterone and Synthetic Progestin Controversies.

Jordan VC, Maximov PY, Fan P.

JAMA Oncol. 2015 Oct;1(7):986-7. doi: 10.1001/jamaoncol.2015.2280. No abstract available.

PMID:
26448286
39.

Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells.

Fan P, Cunliffe HE, Maximov PY, Agboke FA, McDaniel RE, Zou X, Ramos P, Russell ML, Jordan VC.

Mol Cancer Res. 2015 Oct;13(10):1367-76. doi: 10.1158/1541-7786.MCR-14-0494. Epub 2015 Jun 26.

40.

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Fan P, Maximov PY, Curpan RF, Abderrahman B, Jordan VC.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:245-63. doi: 10.1016/j.mce.2015.06.004. Epub 2015 Jun 5. Review.

41.

Obesity and male breast cancer: provocative parallels?

Humphries MP, Jordan VC, Speirs V.

BMC Med. 2015 Jun 4;13:134. doi: 10.1186/s12916-015-0380-x.

42.

Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Jordan VC, Curpan R, Maximov PY.

J Natl Cancer Inst. 2015 Apr 2;107(6):djv075. doi: 10.1093/jnci/djv075. Print 2015 Jun.

43.

Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.

Sengupta S, Biarnes MC, Clarke R, Jordan VC.

Breast Cancer Res Treat. 2015 Apr;150(2):265-78. doi: 10.1007/s10549-015-3319-1. Epub 2015 Feb 27.

44.

The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Jordan VC.

Endocr Relat Cancer. 2015 Feb;22(1):R1-31. doi: 10.1530/ERC-14-0448. Epub 2014 Oct 22. Review.

45.

Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study.

Sweeney EE, Fan P, Jordan VC.

Cancer Res. 2014 Dec 1;74(23):7060-8. doi: 10.1158/0008-5472.CAN-14-1784. Epub 2014 Oct 10.

46.

Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Jordan VC.

J Natl Cancer Inst. 2014 Sep 30;106(11). pii: dju296. doi: 10.1093/jnci/dju296. Print 2014 Nov.

47.

Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.

Maximov PY, McDaniel RE, Fernandes DJ, Bhatta P, Korostyshevskiy VR, Curpan RF, Jordan VC.

J Natl Cancer Inst. 2014 Sep 24;106(10). pii: dju283. doi: 10.1093/jnci/dju283. Print 2014 Oct.

48.

Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells.

Fan P, Cunliffe HE, Griffith OL, Agboke FA, Ramos P, Gray JW, Jordan VC.

Eur J Cancer. 2014 Nov;50(16):2877-86. doi: 10.1016/j.ejca.2014.08.010. Epub 2014 Sep 15.

49.

Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.

Molloy ME, White BE, Gherezghiher T, Michalsen BT, Xiong R, Patel H, Zhao H, Maximov PY, Jordan VC, Thatcher GR, Tonetti DA.

Mol Cancer Ther. 2014 Nov;13(11):2515-26. doi: 10.1158/1535-7163.MCT-14-0319. Epub 2014 Sep 9.

50.

A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer.

Fan P, Agboke FA, Cunliffe HE, Ramos P, Jordan VC.

Eur J Cancer. 2014 Nov;50(16):2866-76. doi: 10.1016/j.ejca.2014.08.011. Epub 2014 Sep 6.

Supplemental Content

Loading ...
Support Center